AGN-1135

AGN-1135 is a monoamine [oxidase inhibitor] that was never marketed. It is the racemic form of rasagiline and is a mixture of the R-enantiomer and S-enantiomer. Like rasagiline, AGN-1135 is a selective monoamine oxidase B inhibitor. Virtually all of the MAOI activity of AGN-1135 lies in rasagiline, which is several orders of magnitude more potent as an MAO-B inhibitor than the S-enantiomer. In relation to this, enantiopure rasagiline was developed and marketed for use as a pharmaceutical drug rather than AGP-1135.